Emdeon Reports Second Quarter 2010 Results

-- 8.3% Revenue Growth Over Second Quarter 2009

NASHVILLE, Tenn., Aug. 5 /PRNewswire-FirstCall/ -- Emdeon Inc. (NYSE: EM), a leading provider of healthcare revenue and payment cycle management solutions, today announced financial results for the second quarter ended June 30, 2010, as summarized below:

($ In millions, except per share amounts)

2Q10


2Q09


% Change

Revenue

$ 243.3


$       224.5


8.3%

Net Income

$     7.3


$         14.5


-49.9%

Net Income per share (diluted)

$   0.05


$         0.14


-64.3%

Non-GAAP Adjusted EBITDA

$   65.2


$         60.4


7.8%

Non-GAAP Adjusted  Net Income per fully diluted share

$   0.22


$          0.24 *


-8.3%

Non-GAAP fully diluted shares

122.6


107.0









* Assuming 2Q10 non-GAAP fully diluted shares of 122.6 million were outstanding at 2Q09, Adjusted Net Income per
fully diluted share for 2Q09 would have been $0.21.



"Our core businesses remain healthy with solid results in payment services, revenue cycle management and pharmacy solutions," said George Lazenby, Emdeon's chief executive officer.  "We were impacted by industry-wide lower healthcare utilization rates this quarter, but our emerging businesses and recent acquisitions are gaining traction.  With an ongoing focus on carefully managing our business, we continue to drive solid bottom line results."

Second quarter revenue was $243.3 million, an increase of 8.3%, compared to $224.5 million for the same period in the prior year.  GAAP operating income for the second quarter of 2010 was $30.6 million compared to $27.7 million for the same period last year, an increase of 10.7%.  Second quarter Adjusted EBITDA grew 7.8% to $65.2 million, or 26.8% of revenue, from Adjusted EBITDA of $60.4 million, or 26.9% of revenue, in the comparable period last year.  

GAAP net income (before noncontrolling interest) for the second quarter of 2010 was $7.3 million compared to GAAP net income of $14.5 million for the same period last year.  GAAP net income per fully diluted share for the second quarter of 2010 was $0.05 compared to $0.14 in the same period last year.  The decline in both GAAP net income and GAAP net income per fully diluted share was driven by fluctuations in income tax expense (benefit) primarily related to a valuation allowance increase in the second quarter of 2010 as compared to a valuation allowance decrease during the same period last year.  Adjusted Net Income per fully diluted share for the second quarter of 2010 was $0.22, using a weighted average fully diluted share count of 122.6 million, compared to $0.24, using a weighted average fully diluted share count of 107.0 million, for the same period last year.

At June 30, 2010, Emdeon's cash and cash equivalents totaled $216.5 million.  Long-term debt under Emdeon's credit facilities was $852.6 million, before unamortized debt discount.

A reconciliation of Emdeon's financial results determined in accordance with U.S. Generally Accepted Accounting Principles (GAAP) to certain non-GAAP financial measures has been provided in the financial statement tables included in this release to supplement its unaudited condensed consolidated financial statements presented on a GAAP basis.  An explanation of these non-GAAP measures is also included below under the heading "Explanation of Non-GAAP Financial Measures."

Financial Outlook

Emdeon maintained its previously announced 2010 annual financial outlook ranges of $1.0 to $1.06 billion for revenue, $266 to $278 million for Adjusted EBITDA and $0.90 to $0.94 for Adjusted Net Income per fully diluted share (using a weighted average share count of 122.4 million).

Notice of Conference Call and Webcast

Emdeon will conduct a conference call/webcast for investors and institutional analysts on Thursday, August 5, 2010 at 5:00 pm Eastern Time/4:00 pm Central Time to discuss Emdeon's financial results.  

To access Emdeon's live conference call and webcast, dial 866-788-0545 (857-350-1683 for international calls) using conference code 80899460 or visit the Investors section of Emdeon's website:  www.emdeon.com.  Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software to access the webcast.  For those unable to listen to the live broadcast, a conference call replay will be available for one week following the conference call by calling 888-286-8010 (617-801-6888 for international calls) using conference code 89646871.  A webcast replay will also be archived on Emdeon's website for at least 30 days following the conference call.

About Emdeon

Emdeon is a leading provider of revenue and payment cycle management solutions, connecting payers, providers and patients in the U.S. healthcare system. Emdeon's product and service offerings integrate and automate key business and administrative functions of its payer and provider customers throughout the patient encounter. Through the use of Emdeon's comprehensive suite of products and services, which are designed to easily integrate with existing technology infrastructures, customers are able to improve efficiency, reduce costs, increase cash flow and more efficiently manage the complex revenue and payment cycle process. For more information, visit www.emdeon.com.

Forward-Looking Statements

Statements made in this press release that express Emdeon's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements, which Emdeon intends to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  These statements often include words such as "may," "will," "should," "believe," "expect," "anticipate," "intend," "plan," "estimate" or similar expressions. Forward-looking statements may include information concerning Emdeon's possible or assumed future results of operations, including descriptions of Emdeon's revenues, profitability, outlook and overall business strategy.  You should not place undue reliance on these statements because they are subject to numerous uncertainties and factors relating to Emdeon's operations and business environment, all of which are difficult to predict and many of which are beyond Emdeon's control.  Although Emdeon believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect Emdeon's actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements, including but not limited to:  effects of competition, including competition from entities that are customers for certain of Emdeon's products and services; Emdeon's ability to maintain relationships with its customers and channel partners; Emdeon's ability to effectively cross-sell its products and services to existing customers and to continue to generate revenue and maintain profitability by developing and successfully deploying new or updated products and services; pricing pressures on Emdeon's products and services; the anticipated benefits from acquisitions not being fully realized or not being realized within the expected time frames; and general economic, business or regulatory conditions affecting the healthcare information technology and services industries; as well as the other risks discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections and elsewhere in Emdeon's Annual Report on Form 10-K for the year ended December 31, 2009, as well as Emdeon's periodic and other reports, filed with the Securities and Exchange Commission.

You should keep in mind that any forward-looking statement made by Emdeon herein, or elsewhere, speaks only as of the date on which made. Emdeon expressly disclaims any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in Emdeon's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Emdeon Inc.

Condensed Consolidated Statements of Operations

(unaudited and amounts in thousands, except share and per share amounts)



For the Three Months


For the Six Months


Ended June 30,


Ended June 30,


2010


2009


2010


2009





Revenue

$   243,289


$     224,541


$   480,568


$   444,426

Costs and expenses:








Cost of operations (exclusive of depreciation and amortization below)

148,444


136,869


292,430


271,607

Development and engineering

8,695


7,305


17,248


14,382

Sales, marketing, general and administrative

26,243


27,423


52,362


51,582

Depreciation and amortization

29,278


25,287


57,053


50,384

Operating income

30,629


27,657


61,475


56,471

Interest income

(5)


(32)


(8)


(53)

Interest expense

15,919


17,169


31,584


35,111

Other

(2,060)


-


(1,770)


-

Income before income tax provision

16,775


10,520


31,669


21,413

Income tax provision (benefit)

9,520


(3,963)


20,152


3,640

Net income

7,255


14,483


11,517


17,773

Net income attributable to noncontrolling interest

3,026


2,044


5,399


4,116

Net income attributable to Emdeon Inc.

$       4,229


$       12,439


$       6,118


$     13,657

Net income per share Class A common stock:








Basic

$         0.05


$           0.16


$         0.07


$         0.18

Diluted

$         0.05


$           0.14


$         0.07


$         0.18

Weighted average common shares outstanding:








Basic

90,061,975


77,413,610


88,879,916


77,413,610

Diluted

90,759,030


100,000,000


90,648,401


77,413,610



Emdeon Inc.

Condensed Consolidated Balance Sheets

(unaudited and amounts in thousands, except share amounts)



June 30,


December 31,


2010


2009

Assets




Current assets:




Cash and cash equivalents

$   216,469


$        211,999

Accounts receivable, net of allowance for doubtful accounts of $4,538 and $4,433 at June 30, 2010 and December 31, 2009, respectively

156,906


151,022

Deferred income tax assets

4,237


4,924

Prepaid expenses and other current assets

14,910


16,632

Total current assets

392,522


384,577

Property and equipment, net

189,738


152,091

Goodwill

739,773


703,027

Intangible assets, net

977,208


989,280

Other assets, net

4,332


1,451

Total assets

$2,303,573


$     2,230,426

Liabilities and equity




Current liabilities:




Accounts payable

$       9,161


$            9,910

Accrued expenses

83,117


72,493

Deferred revenues

10,963


12,153

Current portion of long-term debt

10,905


9,972

Total current liabilities

114,146


104,528

Long-term debt, excluding current portion

838,542


830,710

Deferred income tax liabilities

152,722


145,914

Tax receivable agreement obligations to related parties

140,704


142,044

Other long-term liabilities

43,379


27,361

Commitments and contingencies




Equity:




Preferred stock (par value, $0.00001), 25,000,000 shares authorized and 0 shares issued and outstanding

-


-

Class A common stock (par value, $0.00001),  400,000,000 shares authorized and 90,861,910 and 90,423,941 shares outstanding at June 30, 2010 and December 31, 2009, respectively

1


1

Class B common stock, exchangeable (par value, $0.00001), 52,000,000 shares authorized and 24,689,142 and 24,752,955 shares outstanding at June 30, 2010 and December 31, 2009, respectively

-


-

Additional paid-in capital

741,295


730,941

Contingent consideration

2,667


-

Accumulated other comprehensive loss

(6,116)


(11,198)

Retained earnings

39,822


33,704

Emdeon Inc. equity

777,669


753,448

Noncontrolling interest

236,411


226,421

Total equity

1,014,080


979,869

Total liabilities and equity

$2,303,573


$     2,230,426



Emdeon Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited and amounts in thousands)



For the Six Months


Ended June 30,


2010


2009

Operating activities




Net income

$  11,517


$17,773

Adjustments to reconcile net income to net cash provided by operating activities:




Depreciation and amortization

57,053


50,384

Equity compensation expense

7,847


8,944

Deferred income tax expense (benefit)

7,250


(5,571)

Amortization of debt discount and issuance costs

6,300


5,775

Amortization of discontinued cash flow hedge from other comprehensive loss

2,918


3,962

Other

(1,820)


282

Changes in operating assets and liabilities:




Accounts receivable

814


(4,002)

Prepaid expenses and other

1,909


90

Accounts payable

(1,550)


5,026

Accrued expenses and other liabilities

(456)


(6,216)

Deferred revenues

(1,190)


273

Tax receivable agreement obligations to related parties

(1,480)


-

Net cash provided by operating activities

89,112


76,720

Investing activities




Purchases of property and equipment

(35,772)


(18,446)

Payments for acquisitions, net of cash acquired

(41,991)


(4,118)

Other

(3,000)


-

Net cash used in investing activities

(80,763)


(22,564)

Financing activities




Debt principal payments

(3,775)


(19,775)

Payments on revolver

-


(10,000)

Other

(104)


203

Net cash used in financing activities

(3,879)


(29,572)

Net increase in cash and cash equivalents

4,470


24,584

Cash and cash equivalents at beginning of period

211,999


71,478

Cash and cash equivalents at end of period

$216,469


$96,062



Segment Information

(unaudited and amounts in thousands)




For the Three Months Ended June 30, 2010



For the Three Months Ended June 30, 2009






Corporate &







Corporate &




Payer

Provider

Pharmacy

Eliminations

Consolidated



Payer

Provider

Pharmacy

Eliminations

Consolidated

Revenue from external customers














Claims management


$50,176

$         -

$           -

$               -

$          50,176



$46,256

$         -

$           -

$               -

$          46,256

Payment services


56,504

-

-

-

56,504



52,742

-

-

-

52,742

Patient statements


-

65,705

-

-

65,705



-

68,792

-

-

68,792

Revenue cycle management


-

43,030

-

-

43,030



-

38,037

-

-

38,037

Dental


-

7,947

-

-

7,947



-

7,952

-

-

7,952

Pharmacy services


-

-

19,927

-

19,927



-

-

10,762

-

10,762

Inter-segment revenue


680

72

-

(752)

-



68

508

-

(576)

-

Net revenue


107,360

116,754

19,927

(752)

243,289



99,066

115,289

10,762

(576)

224,541

Costs and expenses:














Cost of operations


70,208

71,702

7,254

(720)

148,444



62,412

72,961

1,940

(444)

136,869

Development and engineering


3,050

3,840

1,805

-

8,695



2,694

3,565

1,046

-

7,305

Sales, marketing, general and administrative


6,115

6,712

1,503

11,913

26,243



6,570

7,810

1,048

11,995

27,423

Segment contribution (1)


$27,987

$ 34,500

$     9,365

$      (11,945)

59,907



$27,390

$ 30,953

$     6,728

$      (12,127)

52,944

Depreciation and amortization






29,278







25,287

Interest income






(5)







(32)

Interest expense






15,919







17,169

Other






(2,060)







-

Income before income tax provision






$          16,775







$          10,520




















For the Six Months Ended June 30, 2010



For the Six Months Ended June 30, 2009






Corporate &







Corporate &




Payer

Provider

Pharmacy

Eliminations

Consolidated



Payer

Provider

Pharmacy

Eliminations

Consolidated

Revenue from external customers














Claims management


$95,652

$         -

$           -

$               -

$          95,652



$91,368

$         -

$           -

$               -

$          91,368

Payment services


113,324

-

-

-

113,324



103,088

-

-

-

103,088

Patient statements


-

132,294

-

-

132,294



-

137,464

-

-

137,464

Revenue cycle management


-

83,791

-

-

83,791



-

75,783

-

-

75,783

Dental


-

15,884

-

-

15,884



-

15,712

-

-

15,712

Pharmacy services


-

-

39,623

-

39,623



-

-

21,011

-

21,011

Inter-segment revenue


1,554

158

-

(1,712)

-



137

972

-

(1,109)

-

Net revenue


210,530

232,127

39,623

(1,712)

480,568



194,593

229,931

21,011

(1,109)

444,426

Costs and expenses:














Cost of operations


137,024

143,075

13,979

(1,648)

292,430



122,288

146,394

3,789

(864)

271,607

Development and engineering


6,064

7,664

3,520

-

17,248



5,326

6,987

2,069

-

14,382

Sales, marketing, general and administrative


12,989

13,523

3,061

22,789

52,362



12,424

15,296

2,026

21,836

51,582

Segment contribution (1)


$54,453

$ 67,865

$   19,063

$      (22,853)

118,528



$54,555

$ 61,254

$   13,127

$      (22,081)

106,855

Depreciation and amortization






57,053







50,384

Interest income






(8)







(53)

Interest expense






31,584







35,111

Other






(1,770)







-

Income before income tax provision






$          31,669







$          21,413





























(1) Segment contribution has been reduced by equity-based compensation expense of $4,172, $6,367, $7,847 and $8,944 for the three months and six months ended June 30, 2010 and 2009, respectively. Segment contribution without such equity-based compensation expense would have been $64,079, $59,311, $126,375 and $115,799 for the three and six months ended June 30, 2010 and 2009, respectively.



Explanation of Non-GAAP Financial Measures

Emdeon's management team believes that in order to properly understand Emdeon's short-term and long-term financial trends, investors may wish to consider the impact of certain non-cash or non-operating items, when used as a supplement to financial performance measures prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP).  These items result from facts and circumstances that vary in frequency and/or impact continuing operations.  In addition, management uses results of operations before such excluded items to evaluate the operational performance of Emdeon as a basis for strategic planning and, in the case of Adjusted EBITDA, as a performance evaluation metric in determining achievement of certain executive and management incentive compensation programs.  Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP.  In addition to the description provided below, reconciliations of GAAP to non-GAAP results are provided in the financial statement tables included in this release.

In this release, Emdeon defines Adjusted EBITDA as EBITDA (which is defined as net income before income tax provision (benefit), net interest expense and depreciation and amortization), plus certain other non-cash or non-operating items (collectively, "EBITDA Adjustments").

In this release, Emdeon defines Adjusted Net Income as the sum of (i) GAAP net income, (ii) EBITDA Adjustments, (iii) non-cash interest expense and (iv) depreciation and amortization expense resulting from adjustments of assets to fair value in connection with acquisition accounting, less income taxes computed based on a normalized income tax rate. Emdeon defines Adjusted Net Income per fully diluted share as the quotient of Adjusted Net Income and weighted average shares outstanding, assuming all potentially dilutive securities are fully dilutive and outstanding shares from their date of grant or issuance.

To properly evaluate Emdeon's business, Emdeon encourages investors to review the GAAP financial information included in this release, and not rely on any single financial measure to evaluate Emdeon's business.  Emdeon also strongly encourages investors to review the reconciliation of GAAP net income and GAAP net income per diluted share to the applicable non-GAAP measures of Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income per fully diluted share.  These non-GAAP measures, as Emdeon defines them, may not be similar to non-GAAP measures used by other companies.

Management uses Adjusted EBITDA and Adjusted Net Income per fully diluted share to facilitate a comparison of Emdeon's operating performance on a consistent basis from period to period that, when viewed in combination with Emdeon's GAAP results, management believes provides a more complete understanding of factors and trends affecting Emdeon's business than GAAP measures alone. Management believes these non-GAAP measures assist Emdeon's board of directors, management, lenders and investors in comparing Emdeon's operating performance on a consistent basis because they remove where applicable, the impact of Emdeon's capital and organizational structure, asset base, acquisition accounting, non-cash charges and non-operating items from Emdeon's operations.

Emdeon also presents Adjusted EBITDA and Adjusted Net Income per fully diluted share on a forward-looking basis as part of its Financial Outlook for 2010.  Emdeon is unable to present a quantitative reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because management cannot predict, with sufficient reliability, contingent payments relating to past and possible future acquisitions, changes in the fair value of Emdeon's interest rate swap agreement and the effect on income taxes of these and other items attributable to Emdeon's organizational structure, all of which are difficult to estimate and  primarily dependent on future events.  

Emdeon Inc.

Reconciliation of GAAP Net Income to Adjusted EBITDA

(unaudited and amounts in thousands)




For the Three Months


For the Six Months



Ended June 30,


Ended June 30,



2010


2009


2010


2009










Net income


$   7,255


$ 14,483


$   11,517


$   17,773

Income tax provision (benefit)


9,520


(3,963)


20,152


3,640

Interest expense, net


15,914


17,137


31,576


35,058

Depreciation and amortization


29,278


25,287


57,053


50,384

EBITDA


61,967


52,944


120,298


106,855










Equity-based compensation


4,172


6,367


7,847


8,944

Acquisition method adjustments


17


405


193


878

Facilities consolidation costs


(27)


175


403


260

Acquisition and divestiture related costs


1,087


546


2,026


546

Tax receivable agreements change in estimate


-


-


(1,480)


-

Contingent consideration adjustments


(2,060)


-


(1,770)


-

EBITDA Adjustments


3,189


7,493


7,219


10,628










Adjusted EBITDA


$ 65,156


$ 60,437


$ 127,517


$ 117,483



Emdeon Inc.

Reconciliation of GAAP Net Income to Adjusted Net Income

(unaudited and amounts in thousands)




For the Three Months


For the Six Months



Ended June 30,


Ended June 30,



2010


2009


2010


2009










Net income


$   7,255


$ 14,483


$ 11,517


$ 17,773

Income tax provision (benefit)


9,520


(3,963)


20,152


3,640

EBITDA Adjustments


3,189


7,493


7,219


10,628

Non-cash interest expense


4,630


4,974


9,218


9,737

Depreciation and amortization resulting from acquisition method adjustments


19,965


18,766


39,141


37,532










Adjusted net income before income taxes


44,559


41,753


87,247


79,310

Normalized income tax provision


17,601


16,492


34,463


31,327










Adjusted Net Income


$ 26,958


$ 25,261


$ 52,784


$ 47,983






























Emdeon Inc.

Reconciliation of Diluted Net Income Per Diluted Share of Class A Common Stock to

Adjusted Net Income Per Fully Diluted Share(1)

(unaudited)




For the Three Months


For the Six Months



Ended June 30,


Ended June 30,



2010


2009


2010


2009

Diluted net income per share Class A common stock


$ 0.05


$ 0.14


$ 0.07


$ 0.18

Impact of assuming full dilution of all outstanding equity instruments for the period


0.00


(0.01)


0.01


(0.01)

Adjustments on a per share basis:









Income tax provision (benefit)


0.08


(0.04)


0.17


0.03

EBITDA Adjustments


0.03


0.07


0.06


0.10

Non-cash interest expense


0.04


0.05


0.08


0.09

Depreciation and amortization resulting from acquisition method adjustments


0.16


0.18


0.32


0.35










Adjusted net income before income taxes


0.36


0.39


0.71


0.74

Normalized income tax provision


0.14


0.15


0.28


0.29

Adjusted Net Income per fully diluted share


$ 0.22


$ 0.24


$ 0.43


$ 0.45





(1) The calculation of Adjusted Net Income per fully diluted share assumes the following equity-based instruments were fully converted into Class
A common stock on their date of issuance:




(shares in thousands)




For the Three Months


For the Six Months




Ended June 30,


Ended June 30,


Weighted average of:


2010


2009


2010


2009


Class A shares outstanding*


90,633


77,414


90,548


77,414


Class B shares outstanding


24,689


24,897


24,707


24,824


Restricted stock units outstanding


759


986


666


955


Options to purchase Class A shares outstanding


6,488


3,691


6,015


3,377


Shares assumed in Adjusted Net Income per fully diluted share calculation


122,569


106,988


121,936


106,570














* Above shares include all potential securities as dilutive and outstanding except for shares issued in connection with 2010 acquisitions and
not contemplated in shares denominator utilized in the 2010 annual Adjusted Net Income per fully diluted share financial outlook range.



SOURCE Emdeon Inc.